摘要
目的观察美罗培南治疗慢性盆腔炎的临床疗效和安全性。方法将90例盆腔炎患者随机分为1.5g治疗组45例(A组)和头孢米诺3.0g对照组45例(B组),每天分3次使用,疗程均为7～14d。比较两组临床疗效、细菌学改变及不良反应情况。结果A、B组临床有效率分别为97.78%、95.56%,二者比较差异无统计学意义(P>0.05)。结论美罗培南治疗慢性盆腔炎安全、有效。
Objective To evaluate the efficacy and safety of meropenem in the treatment of patients pelvic inflammability disease. Methods A total of 90 cases were randomly divided into study group and control group（ each group have 45 patients） , study group （group A ）were treated by meropenem 1.5 g,control group（group B）were treated by cefminox 3.0 g,3 time per day,all patients treated 7-14 days as a course. The clinical efficacy, the bacterial clearance rates and adverse drug reaction of 2 groups were compared. Results The clinical efficacy rate of group A and B were 97.78% and 95.56% respectively,were no statistical differences between 2 groups（ P 〉 0.05 ）. Conclusion Meropenem is an effective and safe agent for treatment of patients with chroriic pelvic inflammability disease.
出处
《中国实用医药》
2008年第19期13-14,共2页
China Practical Medicine
关键词
美罗培南
头孢米诺
慢性盆腔炎
Meropenem
Cefminox
Chroriic pelvic inflaminatory disease
